| Literature DB >> 21941458 |
Quinette Louw1, Karen Grimmer-Somers, Angie Schrikk.
Abstract
BACKGROUND: Virtual reality is consistently reported as effective in reducing pain and anxiety in children during burns dressing changes in recent Western studies. Pain scales are a commonly reported outcome measure. Virtual reality is persuasive for all children in distress during medical procedures, because it is a nonaddictive, novel, and inexpensive form of distraction which can be applied repeatedly with good effect. We intend to use virtual reality in South Africa for the many children hospitalized with severe burns from mechanisms rarely seen in the Western world (paraffin/kerosene stoves exploding, electrical fires, shack/township fires, boiling liquid spills). Many severely burnt children are indigenous South Africans who did not speak English, and whose illiteracy levels, cultures, family dynamics, and experiences of pain potentially invalidate the use of conventional pain scales as outcome measures. The purpose of this study was to identify objective measures with sound psychometric properties and strong clinical utility, to assess distress during burns dressing changes in hospitalized indigenous South African children. Choice of measures was constrained by the burns dressing change environment, the ethics of doing no harm whilst measuring distress in vulnerable children, and of capturing valid measures of distress over the entire burns dressing change procedure.Entities:
Keywords: anxiety; burns; children; distress; measurement; pain; validity
Year: 2011 PMID: 21941458 PMCID: PMC3176143 DOI: 10.2147/JPR.S21821
Source DB: PubMed Journal: J Pain Res ISSN: 1178-7090 Impact factor: 3.133
Figure 1A bath bed with a mobile shower head is used for most dressing changes at the Red Cross Children’s Hospital in Cape Town, South Africa.
Figure 2The three parts of a burn dressing change procedure. Part 1: removal of the soiled burn wound dressing. Part 2: showering and debriding the wound. Part 3: application of new dressings (ointment and bandages). Photographs taken at the Red Cross Children’s Hospital in Cape Town, South Africa.
PRISMA checklist for Von Baeyer and Spagrud30
| Section/topic | Item number | Checklist item | Reported on page number(s) |
|---|---|---|---|
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both | 1 |
| Structured summary | 2 | Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions, and implications of key findings, systematic review | No |
| Rationale | 5 | Describe the rationale for the review in the context of what is already known | 2 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to PICOS | 2 |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, provide registration information including registration number | No |
| Eligibility criteria | 6 | Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication status) used as criteria for eligibility, giving rationale | 6,7 |
| Information sources | 7 | Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched | 5 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated | No |
| Study selection | 9 | State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis) | 5,6 |
| Data collection process | 10 | Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators | 7 |
| Data items | 11 | List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made | 5 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis | No |
| Summary measures | 13 | State the principal summary measures (such as risk ratio, difference in means) | 1 |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistic) for each meta-analysis | 4 |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selective reporting within studies) | 2 |
| Additional analyses | 16 | Describe methods of additional analyses (such as sensitivity or subgroup analyses, metaregression), if done, indicating which were prespecified | No |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram | No |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the citations | No |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12) | No |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a Forest plot | NA |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency | No |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see item 15) | No |
| Additional analysis | 23 | Give results of additional analyses, if done (such as sensitivity or subgroup analyses, metaregression, see item 16) | No |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as health care providers, users, and policy makers) | 7 |
| Limitations | 25 | Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified research, reporting bias) | No |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research | 10 |
| Funding | 27 | Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic review | 10 |
Abbreviations: PICOS, participants, interventions, comparisons, outcomes, and study design; NA, not available.
Studies identified on the use of virtual reality in pediatric patients (aged 5–17 years), taken from Morris et al16 and additional literature searches
| Study | Age group | Outcome measures |
|---|---|---|
| Das et al | 6–16 years | Pain measured by FACES pain scale and visual analog scale |
| Chan et al | Mean age 6.54 years | Pain measured by FACES pain scale, usability, and modified presence questionnaire |
| Van Twillert et al | 8–65 years | Pain and anxiety measured by visual analog thermometer and Spielberger State-Trait Anxiety Inventory Scale |
| Sharar et al | 6–65 years | Pain measured by 10 point Graphic Rating Scale |
| Hoffman et al | 9–40 years | Pain measured by 10 point Graphic Rating Scale |
| Hoffman et al | Two cases (16 and 17 years) | 100 mm scales capturing sensory and affective pain ratings, anxiety and subjective estimates of time spent thinking about pain during the procedure |
| Hoffman et al | 9–32 years | Visual analog scales to assess:
Time spent thinking about pain Unpleasantness Bothersomeness Worst pain Average pain |
| Mott et al | 3–14 years | Pain scores |
Scales used to measure observed behaviors, extracted from Cohen et al,28 Von Baeyer and Spagrud,30 and Blount and Loiselle27
| Scale | Application | Type | Cohen et al | Von Baeyer and Spagrud | Blount and Loiselle |
|---|---|---|---|---|---|
| Varni/Thompson | Chronic pain intensity, location, pain qualities via self-report and parent/doctor proxy report | Questionnaire | ✓ | ||
| Observational Scale of Behavioral Distress | Procedural pain and distress | Video and later scoring of distress behaviors | ✓ | ✓ | ✓ |
| Child-Adult Medical Procedure Interaction Scale | Behavioral distress in children associated with medical procedures | Video and transcripts of conversations scored later for distress behaviors | ✓ | ✓ | |
| Procedure Behavior Checklist | Pain-related distress, fear, and anxiety during medical procedure | Observation | ✓ | ✓ | ✓ |
| Children’s Hospital of Eastern Ontario Pain Scale | Procedural pain | Observation | ✓ | ✓ | ✓ |
| Premature Infant Pain Profile | Not relevant | Observation | ✓ | ||
| COMFORT | Critical care settings | Observation | ✓ | ✓ | ✓ |
| Face, Legs, Arms, Cry, Consolability | Postoperative and procedural pain in hospital | Observation | ✓ | ✓ | |
| Parents’ Post-Operative Pain Measure | Postoperative pain at home | ✓ |
A list of potential measures of distress to assess the effectiveness of virtual reality during burns dressings in pediatric patients
| Child | Parent | Health care provider | |
|---|---|---|---|
| Perspectives on pain experienced | CAMPIS-SF | Proxy reports FACES scale or other visual analog | Ease of completing dressing change |
| Classifications, types, and frequencies of behavior | FLACC | ||
| Objective measures | Heart rate | Heart rate | Time taken for procedure to be completed |
Abbreviations: CAMPIS-SF, Child-Adult Medical Procedure Interaction Scale-Short Form; FLACC, Face, Legs, Arms, Cry, Consolability; PBCL, Procedure Behavior Checklist.
PRISMA checklist for Stinson et al29
| Section/topic | Item number | Checklist item | Reported on page number |
|---|---|---|---|
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both | 143 |
| Structured summary | 2 | Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review | 143 |
| Rationale | 5 | Describe the rationale for the review in the context of what is already known | 144 (Introduction) |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to PICOS | 144 (SR of outcomes; no intervention required) |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, provide registration information including registration number | No |
| Eligibility criteria | 6 | Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication status) used as criteria for eligibility, giving rationale | 144 |
| Information sources | 7 | Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched | 144 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated | No |
| Study selection | 9 | State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis) | 145 |
| Data collection process | 10 | Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators | 145 |
| Data items | 11 | List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made | 145 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis | 145 |
| Summary measures | 13 | State the principal summary measures (such as risk ratio, difference in means) | No |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistic) for each meta-analysis | No |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selective reporting within studies) | No |
| Additional analyses | 16 | Describe methods of additional analyses (such as sensitivity or subgroup analyses, metaregression), if done, indicating which were prespecified | No |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram | No |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the citations | No |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12) | No |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a Forest plot | No (results are presented for individual outcomes not for individual studies) |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency | No |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see item 15) | No |
| Additional analysis | 23 | Give results of additional analyses, if done (such as sensitivity or subgroup analyses, metaregression, see item 16) | No/NA |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as health care providers, users, and policy makers) | No |
| Limitations | 25 | Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified research, reporting bias) | No |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research | No |
| Funding | 27 | Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic review | No (but unsure, could be funded by Ped-IMMPACT group but it is unclear) |
Abbreviations: PICOS, participants, interventions, comparisons, outcomes, and study design; NA, not available; Ped-IMMPACT, Pediatric Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials.
PRISMA checklist for Blount and Loiselle27
| Section/topic | Item number | Checklist item | Reported on page number |
|---|---|---|---|
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both | No |
| Structured summary | 2 | Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review | No |
| Rationale | 5 | Describe the rationale for the review in the context of what is already known | 47 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS) | No |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, provide registration information including registration number | No |
| Eligibility criteria | 6 | Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication status) used as criteria for eligibility, giving rationale | No |
| Information sources | 7 | Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched | No |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated | No |
| Study selection | 9 | State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis) | No |
| Data collection process | 10 | Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators | No |
| Data items | 11 | List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made | No |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis | No |
| Summary measures | 13 | State the principal summary measures (such as risk ratio, difference in means) | No |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistic) for each meta-analysis | No |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selective reporting within studies) | No |
| Additional analyses | 16 | Describe methods of additional analyses (such as sensitivity or subgroup analyses, metaregression), if done, indicating which were prespecified | No |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram | No |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the citations | No |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12) | No |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a Forest plot | No |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency | No |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see item 15) | No |
| Additional analysis | 23 | Give results of additional analyses, if done (such as sensitivity or subgroup analyses, metaregression, see item 16) | No |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as health care providers, users, and policy makers) | No |
| Limitations | 25 | Discuss limitations at study and outcome level (such as risk of bias), and at review level such as incomplete retrieval of identified research, reporting bias) | No |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research | 51 |
| Funding | 27 | Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic review | No |
Reproduced with permission from Blount RL, Loiselle KA. Behavioural assessment of pediatric pain. Pain Res Manage. 2009;14:47–52.
Abbreviation: PICOS, participants, interventions, comparisons, outcomes, and study design.
PRISMA checklist for Cohen et al28
| Section/topic | Item number | Checklist item | Reported on page number |
|---|---|---|---|
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both | No |
| Structured summary | 2 | Provide a structured summary including, as applicable, background, objectives, data sources, study eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, conclusions and implications of key findings, systematic review | No (methods section not adequate) |
| Rationale | 5 | Describe the rationale for the review in the context of what is already known | 939,940 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to PICOS | No |
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if available, provide registration information including registration number | No |
| Eligibility criteria | 6 | Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as years considered, language, publication status) used as criteria for eligibility, giving rationale | No (not in detail) |
| Information sources | 7 | Describe all information sources (such as databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched | No |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated | No |
| Study selection | 9 | State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis) | No |
| Data collection process | 10 | Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators | No |
| Data items | 11 | List and define all variables for which data were sought (such as PICOS, funding sources) and any assumptions and simplifications made | No |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis | No (outcomes were assessed but not individual studies) |
| Summary measures | 13 | State the principal summary measures (such as risk ratio, difference in means) | No |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (such as I2 statistic) for each meta-analysis | No (synthesis was performed individual outcomes as well established, approaching well established and promising assessment) |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, selective reporting within studies) | No |
| Additional analyses | 16 | Describe methods of additional analyses (such as sensitivity or subgroup analyses, metaregression), if done, indicating which were pre-specified | No |
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram | No |
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-up period) and provide the citations | No (presented information as per outcome not per study) |
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). | No |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present for each study (a) simple summary data for each intervention group and (b) effect estimates and confidence intervals, ideally with a Forest plot | No |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency | No |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see item 15) | No |
| Additional analysis | 23 | Give results of additional analyses, if done (such as sensitivity or subgroup analyses, metaregression, see item 16) | No (Subgroup analysis: |
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (such as health care providers, users, and policy makers) | No |
| Limitations | 25 | Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as incomplete retrieval of identified research, reporting bias) | No |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research | 949 |
| Funding | 27 | Describe sources of funding for the systematic review and other support (such as supply of data) and role of funders for the systematic review | No |
Reproduced with permission from Cohen LL, Lemanek K, Blount RL, et al. Evidence-based assessment of pediatric pain. J Pediatr Psychol. 2008;33:939–955.
Abbreviation: PICOS, participants, interventions, comparisons, outcomes, and study design.